Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Filtration fraction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    150 result(s) found for: Filtration fraction. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2016-002828-85 Sponsor Protocol Number: RG_15-114 Start Date*: 2017-04-28
    Sponsor Name:University of Birmingham
    Full Title: Paediatric Hepatic International Tumour Trial
    Medical condition: Hepatoblastoma and Hepatocellular Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062001 Hepatoblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019830 Hepatocellular carcinoma resectable LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) DE (Ongoing) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) AT (Ongoing) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003589-25 Sponsor Protocol Number: Levo-AKI Start Date*: 2014-11-11
    Sponsor Name:Sahlgrenska Universitetssjukhuset/Sahlgrenska
    Full Title: The effect of levosimendan, on renal blood flow, function and oxygen uptake during acute renal failure after cardiac surgery
    Medical condition: Acute kidney injury postoperatively in connection with heart surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002168-17 Sponsor Protocol Number: BAY94-8862/16275 Start Date*: 2015-12-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in...
    Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    20.0 100000004849 10066498 Cardiac failure chronic aggravated LLT
    21.0 100000004857 10076408 Chronic kidney disease stage 1 LLT
    21.0 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001341-27 Sponsor Protocol Number: Empire-2017 Start Date*: 2017-05-29
    Sponsor Name:Morten Schou
    Full Title: Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF)
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000481-14 Sponsor Protocol Number: APHP210166 Start Date*: 2021-12-20
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Cardiometabolic effects of dapagliflozin in heart failure with reduced ejection fraction: an exploratory study.
    Medical condition: Heart failure with reduced ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007881-45 Sponsor Protocol Number: SPP100ANL02T Start Date*: 2009-03-12
    Sponsor Name:University Medical Center Groningen
    Full Title: A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients w...
    Medical condition: Patients with chronic heart failure and reduced glomerular filtration rate.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038443 Renal failure and impairment HLT
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003053-26 Sponsor Protocol Number: TMC-BIV-05-01 Start Date*: 2005-12-08
    Sponsor Name:The Medicines Company UK Ltd
    Full Title: The ZBMUF trial: an open-label randomised study of the effects of ultra-filtration and high dose aprotinin on bivalirudin pharmacokinetics during and/or after cardiopulmonary bypass surgery
    Medical condition: This trial will involve approximately 42 patients requiring coronary artery bypass graft surgery (CABG).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001840-37 Sponsor Protocol Number: 2017-001840-37 Start Date*: 2019-01-15
    Sponsor Name:VU University Medical Center
    Full Title: ERtugliflozin triAl in DIabetes with preserved or reduced ejeCtion FrAcTion mEchanistic evaluation in Heart Failure: "ERADICATE-HF"
    Medical condition: Diabetes Mellitus Type 2 and Heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015834-31 Sponsor Protocol Number: CLCZ696B2314 Start Date*: 2010-01-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chro...
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004849 10008502 CHF LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) IS (Completed) GB (Completed) ES (Prematurely Ended) DE (Completed) HU (Completed) NL (Prematurely Ended) SE (Completed) IT (Prematurely Ended) RO (Completed) SK (Completed) FI (Completed) FR (Completed) DK (Completed) BE (Completed) CZ (Completed) LT (Completed) EE (Completed) LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-013159-31 Sponsor Protocol Number: CS/2009/3292 Start Date*: 2010-02-25
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Preoperative volume replacement vs. usual care in diabetic patients having CABG surgery: a randomised controlled trial
    Medical condition: Coronary artery bypass grafting in diabetic patients
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008287-28 Sponsor Protocol Number: ALI-FRA-0030-I Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Erlangen
    Full Title: Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes
    Medical condition: Patients with prediabetes (either impaired glucose tolerance or imparied fasting glucose) and no obvious diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001704-37 Sponsor Protocol Number: CSPP100A2340 Start Date*: 2006-11-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling ...
    Medical condition: Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) DE (Completed) SE (Completed) BE (Completed) CZ (Completed) HU (Completed) GB (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002278-30 Sponsor Protocol Number: CRC2012LINA Start Date*: 2012-08-13
    Sponsor Name:University Hospital Erlangen
    Full Title: Effects of Linagliptin on Renal Endothelium Function in Patients with Type 2 Diabetes.
    Medical condition: Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006838-17 Sponsor Protocol Number: CICL670A2123 Start Date*: 2007-09-13
    Sponsor Name:NOVARTIS FARMA
    Full Title: Phase I study to examine the effect of deferasirox on renal hemodynamics in β-thalassemia patients with transfusional iron overload
    Medical condition: thalassemia
    Disease: Version SOC Term Classification Code Term Level
    6.1 10022958 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004086-15 Sponsor Protocol Number: 1000 Start Date*: 2005-05-17
    Sponsor Name:University Hospital of Frankfurt, Department of Cardiology
    Full Title: Comparison of nephrotoxic effects of the contrast dyes iodixanol (iso-osmolar, non-ionic, dimer) and ioversol (low-osmolar, non-ionic, monomer) in patients with impaired renal function and severe h...
    Medical condition: Coronary angiography in patients with known coronary artery disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003888-23 Sponsor Protocol Number: 09/2005/2007 Start Date*: 2006-03-23
    Sponsor Name:University College London
    Full Title: A phase II multicentre trial of CVP, rituximab and gemcitabine for the treatment of patients with newly diagnosed diffuse large b-cell lymphoma considered unsuitable for r-chop chemotherapy
    Medical condition: Large B cell non-Hodgkin’s lymphoma (DLBCL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003736-13 Sponsor Protocol Number: CCTL019B2205J Start Date*: 2017-09-29
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
    Medical condition: Paediatric patients with B-cell acute lymphoblastic leukaemia and lymphoma who are refractory, relapsed to prior treatments
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-002614-12 Sponsor Protocol Number: ESR-17-13447(DAPA-HF) Start Date*: 2019-02-08
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Short-term Effects of Dapagliflozin on Peak VO2 in Patients with Heart Failure with Reduced Ejection Fraction and Type 2 Diabetes
    Medical condition: Stable symptomatic heart failure with reduced ejection fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004060-40 Sponsor Protocol Number: AGO15 Start Date*: 2008-03-13
    Sponsor Name:Studienzentrale AGO Austria
    Full Title: Phase II multicenter trial of the Austrian AGO of the combination of liposomal Doxorubicin (Myocet®) and Carboplatin in primary advanced or metastatic and recurrent endometrial cancer
    Medical condition: primary advanced or recurrent/metastatic endometrial cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000186-40 Sponsor Protocol Number: B1931036 Start Date*: 2022-10-07
    Sponsor Name:Pfizer Inc.
    Full Title: A PROSPECTIVE, RANDOMIZED, OPEN-LABEL PHASE 2 STUDY TO EVALUATE THE SUPERIORITY OF INOTUZUMAB OZOGAMICIN MONOTHERAPY VERSUS ALLR3 FOR INDUCTION TREATMENT OF CHILDHOOD HIGH RISK FIRST RELAPSE B-CELL...
    Medical condition: Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Trial now transitioned) CZ (Ongoing) NL (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:52:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA